Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBIT Margin (2022 - 2025)

Bioregenx's EBIT Margin history spans 4 years, with the latest figure at 242.62% for Q4 2025.

  • Quarterly results put EBIT Margin at 242.62% for Q4 2025, up 373506.0% from a year ago — trailing twelve months through Dec 2025 was 67.08% (up 90567.0% YoY), and the annual figure for FY2025 was 67.08%, up 90567.0%.
  • EBIT Margin for Q4 2025 was 242.62% at Bioregenx, down from 1.67% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 1.67% in Q3 2025 to a low of 3977.69% in Q4 2024.
  • The 4-year median for EBIT Margin is 61.89% (2022), against an average of 391.27%.
  • The sharpest move saw EBIT Margin plummeted -394649bps in 2024, then skyrocketed 373506bps in 2025.
  • Year by year, EBIT Margin stood at 62.09% in 2022, then skyrocketed by 50bps to 31.2% in 2023, then plummeted by -12648bps to 3977.69% in 2024, then skyrocketed by 94bps to 242.62% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 242.62%, 1.67%, and 24.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.